Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic.
Ramurthy, S., Taft, B.R., Aversa, R.J., Barsanti, P.A., Burger, M.T., Lou, Y., Nishiguchi, G.A., Rico, A., Setti, L., Smith, A., Subramanian, S., Tamez, V., Tanner, H., Wan, L., Hu, C., Appleton, B.A., Mamo, M., Tandeske, L., Tellew, J.E., Huang, S., Yue, Q., Chaudhary, A., Tian, H., Iyer, R., Hassan, A.Q., Mathews Griner, L.A., La Bonte, L.R., Cooke, V.G., Van Abbema, A., Merritt, H., Gampa, K., Feng, F., Yuan, J., Mishina, Y., Wang, Y., Haling, J.R., Vaziri, S., Hekmat-Nejad, M., Polyakov, V., Zang, R., Sethuraman, V., Amiri, P., Singh, M., Sellers, W.R., Lees, E., Shao, W., Dillon, M.P., Stuart, D.D.
J.Med.Chem.
